Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive forms of idiopathic interstitial pneumonias, characterized by chronic and progressive fibrosis subverting the lung’s architecture, pulmonary functional decline, progressive respiratory failure, and high mortality (median survival 3 years after diagnosis). Among the mechanisms associated with disease onset and progression, it has been hypothesized that IPF lungs might be affected either by a regenerative deficit of the alveolar epithelium or by a dysregulation of repair mechanisms in response to alveolar and vascular damage. This latter might be related to the progressive dysfunction and exhaustion of the resident stem cells together with a process of cellular and tissue senescence. The role of endogenous mesenchymal stromal/stem cells (MSCs) resident in the lung in the homeostasis of these mechanisms is still a matter of debate. Although endogenous MSCs may play a critical role in lung repair, they are also involved in cellular senescence and tissue ageing processes with loss of lung regenerative potential. In addition, MSCs have immunomodulatory properties and can secrete anti-fibroticfactors. Thus, MSCs obtained from other sources administered systemically or directly into the lung have been investigated for lung epithelial repair and have been explored as a potential therapy for the treatment of lung diseases including IPF. Given these multiple potential roles of MSCs, this review aims both at elucidating the role of resident lung MSCs in IPF pathogenesis and the role of administered MSCs from other sources for potential IPF therapies.

Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution? / Samarelli, Av; Tonelli, R; Heijink, I; Martin Medina, A; Marchioni, A; Bruzzi, G; Castaniere, I; Andrisani, D; Gozzi, F; Manicardi, L; Moretti, A; Cerri, S; Fantini, R; Tabbì, L; Nani, C; Mastrolia, I; Weiss, Dj; Dominici, M; Clini, E.. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 12:(2021), pp. 1-21. [10.3389/fphar.2021.692551]

Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution?

Andrisani, D;Cerri, S;Dominici, M;Clini, E.
2021-01-01

Abstract

Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive forms of idiopathic interstitial pneumonias, characterized by chronic and progressive fibrosis subverting the lung’s architecture, pulmonary functional decline, progressive respiratory failure, and high mortality (median survival 3 years after diagnosis). Among the mechanisms associated with disease onset and progression, it has been hypothesized that IPF lungs might be affected either by a regenerative deficit of the alveolar epithelium or by a dysregulation of repair mechanisms in response to alveolar and vascular damage. This latter might be related to the progressive dysfunction and exhaustion of the resident stem cells together with a process of cellular and tissue senescence. The role of endogenous mesenchymal stromal/stem cells (MSCs) resident in the lung in the homeostasis of these mechanisms is still a matter of debate. Although endogenous MSCs may play a critical role in lung repair, they are also involved in cellular senescence and tissue ageing processes with loss of lung regenerative potential. In addition, MSCs have immunomodulatory properties and can secrete anti-fibroticfactors. Thus, MSCs obtained from other sources administered systemically or directly into the lung have been investigated for lung epithelial repair and have been explored as a potential therapy for the treatment of lung diseases including IPF. Given these multiple potential roles of MSCs, this review aims both at elucidating the role of resident lung MSCs in IPF pathogenesis and the role of administered MSCs from other sources for potential IPF therapies.
5-lug-2021
12
1
21
Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution? / Samarelli, Av; Tonelli, R; Heijink, I; Martin Medina, A; Marchioni, A; Bruzzi, G; Castaniere, I; Andrisani, D; Gozzi, F; Manicardi, L; Moretti, A; Cerri, S; Fantini, R; Tabbì, L; Nani, C; Mastrolia, I; Weiss, Dj; Dominici, M; Clini, E.. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 12:(2021), pp. 1-21. [10.3389/fphar.2021.692551]
Samarelli, Av; Tonelli, R; Heijink, I; Martin Medina, A; Marchioni, A; Bruzzi, G; Castaniere, I; Andrisani, D; Gozzi, F; Manicardi, L; Moretti, A; Cerri, S; Fantini, R; Tabbì, L; Nani, C; Mastrolia, I; Weiss, Dj; Dominici, M; Clini, E.
File in questo prodotto:
File Dimensione Formato  
Samarelli (Role of MSCs in Pulmonary Fibrosis- review 2021).pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.65 MB
Formato Adobe PDF
1.65 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1247955
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact